Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

GSK raises $1.5 billion from offloading Haleon stake at a discount

by Staff GBAF Publications Ltd
0 comment

GSK raises $1.5 billion from offloading Haleon stake at a discount

(Reuters) – GSK has raised 1.25 billion pounds ($1.52 billion) from selling its entire remaining stake in consumer healthcare firm Haleon, the British drugmaker said on Friday.

GSK sold around 385 million shares at 324 pence apiece, amounting to a 4.2% stake in Haleon. The company was formed in a merger of GSK and Pfizer’s consumer healthcare businesses in 2019.

The sale was at a discount of about 2.5% to Haleon’s last close of 332.4 pence on Thursday.

The sell-off will allow GSK to sharpen its focus on vaccines, cancer and infectious diseases, which has been CEO Emma Walmsley’s major focus to boost earnings at the drugmaker under its current strategy.

Haleon, in which GSK initially had a nearly 13% stake, was spun out and listed on the London Stock Exchange in July 2022.

This sale marks GSK’s fourth offload in the Sensodyne toothpaste maker in just over a year.

($1 = 0.7898 pounds)


(Reporting by Prerna Bedi in Bengaluru; Editing by Varun H K)